Alternative Antiepileptic Options for Seizure Management

Status Epilepticus and Acute Seizure Management

Valproic acid provides comparable seizure‑cessation rates to levetiracetam in refractory status epilepticus (≈68 % vs 73 %). This evidence comes from emergency‑medicine studies and supports its use as a cost‑effective alternative, though clinicians must monitor for drug interactions and avoid use in women of child‑bearing potential. [1][2]
Phenytoin or fosphenytoin achieve seizure control in about 56 % of status‑epilepticus cases, but are associated with more pronounced side‑effects and numerous drug interactions (e.g., with steroids and chemotherapy agents). These data are derived from emergency‑medicine research. [5][2]
Generic fosphenytoin is now available, offering substantial cost reduction compared with brand formulations. 6

Lamotrigine is endorsed as a first‑line option alongside levetiracetam for brain‑tumor‑related seizures by the EANO‑ESMO guidelines, demonstrating good antiseizure efficacy and overall tolerability. [3][4]
Lamotrigine requires several weeks of gradual titration to reach therapeutic plasma levels before full efficacy is achieved. 3
Valproic acid remains a solid choice for long‑term seizure control, offering effective seizure reduction and generally good tolerability; however, regular monitoring for drug interactions is essential. [3][4]
Phenobarbital, phenytoin, and carbamazepine are no longer recommended as first‑line agents for chronic seizure management because of their unfavorable side‑effect profiles and extensive drug‑interaction potential. [3][4]